Abstract:BACKGROUND: The prognosis of malignant hematologic diseases has improved greatly with the application of the hematopoietic stem cell transplantation. Peripheral blood stem cell transplantation (PBSCT) has been used as an alternative to bone marrow transplantation (BMT). OBJECTIVE: To observe curative effect and clinical outcome in 53 patients with hematological malignancy undergoing allogeneic peripheral blood stem cell transplantation (allo-PBSCT) or autologous peripheral blood stem cell transplantation (auto-PBSCT). DESIGN: Randomized controlled study. SETTING: BMT Center, Hematology Department of the First Affiliated Hospital of Zhengzhou University. PARTICIPANTS: From July 2003 to May 2006, 53 patients (33 males and 20 females) with a median age of 37 years underwent PBSCT. Thirty-five patients received allo-PBSCT, including 13 of acute myelocytic leukemia (AML), 7 of acute lymphocytic leukemia (ALL), 10 of chronic myelocytic leukemia (CML), 2 of multiple myeloma (MM), and 3 of myelodysplastic syndrome (MDS). Eighteen patients underwent auto-PBSCT, including 7 AML, 6 ALL, 2 MM, and 3 non-Hodgkin lymphoma (NHL). Thirty-three donors (20 males and 13 females) with a median age of 35 age in the allo-PBSCT were HLA-identical siblings, 2 donors (5.7%) had one mismatch. Sixteen allografts were sex mismatched. Study was authorized by the Ethic committee of the hospital, and all patients had signed an inform consent. METHODS: ① PBSC were mobilized with granulocyte colony-stimulating factor (G-CSF) or chemotherapy combined with G-CSF. A median of 6.2×106 CD34+ cells/kg was infused for allo-PBSCT and 3.0×106 CD34+ cells/kg was infused for auto-PBSCT. Amended BU/CY was used as conditioning regimen in allo-PBSCT and MAC was used in auto-PBSCT. Methotrexate (MTX) combined with cyclosporine A (CsA) and mycophenolate mofetil (MMF) was used as graft-versus-host disease (GVHD) prophylaxis. ALG was used in 1 patient with 1 locus mismatched in allo-PBSCT. ② Time to engraftment was calculated from the time of transplantation to neutrophil recovery ≥ 0.5×109 L-1 and platelet recovery ≥ 20×109 L-1, GVHD and relapse were observed until 1 year of follow-up. MAIN OUTCOME MEASURES: ① Time to neutrophil and platelet recovery; ② GVHD occurrence after transplantation; ③ outcome of treatment. RESULTS: All the 53 patients were analyzed. ① Engraftment of neutrophils (> 0.5×109 L-1) and platelets (> 20×109 L-1) was achieved at a median of 13 days for neutrophils and 19 days for platelets in auto-PBSCT, and 12 days and 15 days respectively in allo-PBSCT. ② In allo-PBSCT, I-VI acute GVHD occurred in 31.4% cases, and chronic GVHD developed in 71.4% cases. ③ The relapse rate was 38.9% in auto-PBSCT, and 5.7% in allo-PBSCT. CONCLUSION: PBSCT can provide rapid hematopoietic reconstitution. It is an important method to cure the malignant hematologic diseases.

Clinical Analysis on Autologous Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 206 Cases

Clinical Analysis of Autologous Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 231 Cases

Clinical Analysis of Auto Peripheral Blood Stem Cell Transplantation for Treatment of Hematologic Malignancies

[Long Term Curative Effects and Prognostic Analysis of Stem Cell Transplantation for Treating Patients with Peripheral T Cell Lymphoma].

Clinical application study on hematological malignancies treated by autologous peripheral blood hematopoietic stem cell transplantation

Analysis of autologous hemopoietic stem cell transplantation for 61 patients with hematological malignancies

Clinical Analysis on Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies in 283 Cases

Autologous Peripheral Blood Stem Cell Transplantation Is More Therapeutically Effective In The Patients With Hematologic And Solid Tumors.

Clinical Observation of Patients with Hematological Malignancies Treated by Peripheral Blood Stem Cell Transplantation

Clinical Efficacy of Peripheral Blood Stem Cell Transplantation in the Treatment of Hematologic Diseases:Observation of 50 Cases

Effect of autologons peripheral hematopoietic stem cell transplantation on remission and survival rates in patients with lymphoma

[Clinical analysis of 81 cases of malignant lymphoma treated with autologous hematopoietic stem cell transplantation].

Autologous or allogeneic peripheral blood stem cell transplantation for the malignant hematologic diseases in 53 cases

Evaluation of Effects of Autologous Peripheral Blood Stem Cell Transplantation on the Response Rates and Survival Rates in the Patients with Refractory or Relapsed Hodgkin Lymphoma and Grey Zone Lymphoma

Allogeneic peripheral blood stem cell transplantation for 75 cases of hematologic malignancies]

Efficacy of Hematopoietic Stem Cell Transplantation in the Treatment of 110 Cases Hematologic Malignancies

Clinical Observation of Patients with Hematologic Malignancies Treated with Hematopoietic Stem Cell Transplantation.

A Clinical Comparison of CD34+ Selected Autologous Peripheral Blood Stem Cells Transplantation in Malignant Hematologic Disease

Effect of hematopoietic stem cell transplantation in malignant hematologic disease of lymphatic system]

Clinical Observation and Long-time Follow-up of Patients with Malignant Lymphoma Treated with Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation

A Clinical Study of the Hematopoietic Stem Cell Transplantation in 112 Patients with Leukemia and Other Malignant Diseases